(Note: CoLabs Int’l Corp. withdrew its IPO plans in an SEC filing dated Jan. 30, 2024. The company filed its S-1 on March 27, 2023.)

CoLabs Int’l Corp. is an over-the-counter (“OTC”) pharmaceutical company with multi-market applications for our revolutionary targeted drug delivery system which is identified as QuantaSphere® Technology (QS®). (Incorporated in Nevada)

We currently hold 29 issued patents and have an additional 15 patent applications pending.

Our technology places OTC drugs, pharmaceuticals, and chemicals into micro-sized electrostatically charged encapsulates as well as into other types of micro-encapsulates. These encapsulates are then suspended in uniquely designed formulations. This formulation of a highly advanced micro-technology can: target the delivery of topically applied drugs; limit unwanted absorption of chemicals, drugs, and cosmetics through the skin; and provide a designed release of active ingredients with a prescribed depth of skin penetration.

We have already developed commercially unique and innovative targeted skin delivery systems for topical pharmacology. Our technology limits unwanted side effects that can occur as a result of uncontrolled absorption of topical medications through the skin. The penetration of chemicals through the skin can have serious impact on the body’s organs and systems. Our current applications include anti-bacterial/viral sanitizers/soaps, sunscreens, pest-repellents, and healing cosmetic lotions. For consumers, we provide elegant skin delivery of topically applied drugs and cosmetics. This combined end purpose is the unique foundation of our technology.

*Note: Net loss and revenue figures are for the year ended Dec. 31, 2022.

(Note: CoLabs Int’l, Corp. filed its S-1 on March 27, 2023.)